INDISCRIMINATE USE OF GLP-1 ANALOGUES, SUCH AS SEMAGLUTIDE (OZEMPIC®), FOR AESTHETIC PURPOSES AND MULTIDISCIPLINARY ACTION IN CARE AND RISK PREVENTION. EIC [Internet]. 2025 Oct. 20 [cited 2026 Feb. 20];:342-56. Available from: https://periodicos.newsciencepubl.com/editoraimpacto/article/view/9073